Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study

Casper N Bang; Anders Greve; Kurt Boman; Kenneth Egstrup; Christa Gohlke-Baerwolf; Lars Valeur Køber; Christoph A Nienaber; Simon Ray; Anne B Rossebø; Kristian Wachtell

doi:10.1016/j.ahj.2012.01.026

Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study

Casper N Bang
, Anders Greve
, Kurt Boman
, Kenneth Egstrup
, Christa Gohlke-Baerwolf
, Lars Valeur Køber
, Christoph A Nienaber
, Simon Ray
, Anne B Rossebø
, Kristian Wachtell

Rigshospitalet

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

Lipid-lowering drugs, particularly statins, have anti-inflammatory and antioxidant properties that may prevent atrial fibrillation (AF). This effect has not been investigated on new-onset AF in asymptomatic patients with aortic stenosis (AS).

Originalsprog	Engelsk
Tidsskrift	American Heart Journal
Vol/bind	163
Udgave nummer	4
Sider (fra-til)	690-696
ISSN	0002-8703
DOI	https://doi.org/10.1016/j.ahj.2012.01.026
Status	Udgivet - 2012

Dokumenter og links

10.1016/j.ahj.2012.01.026

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Bang, C. N., Greve, A., Boman, K., Egstrup, K., Gohlke-Baerwolf, C., Køber, L. V., Nienaber, C. A., Ray, S., Rossebø, A. B., & Wachtell, K. (2012). Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. American Heart Journal, 163(4), 690-696. https://doi.org/10.1016/j.ahj.2012.01.026

@article{a7b2d6692d8f45ed9cdb95f94da3d9f4,

title = "Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study",

abstract = "Lipid-lowering drugs, particularly statins, have anti-inflammatory and antioxidant properties that may prevent atrial fibrillation (AF). This effect has not been investigated on new-onset AF in asymptomatic patients with aortic stenosis (AS).",

keywords = "Aged, Aged, 80 and over, Anticholesteremic Agents, Aortic Valve Stenosis, Atrial Fibrillation, Azetidines, Double-Blind Method, Female, Heart Ventricles, Humans, Male, Middle Aged, Multivariate Analysis, Prognosis, Simvastatin, Stroke, Time Factors",

author = "Bang, \{Casper N\} and Anders Greve and Kurt Boman and Kenneth Egstrup and Christa Gohlke-Baerwolf and K{\o}ber, \{Lars Valeur\} and Nienaber, \{Christoph A\} and Simon Ray and Rosseb{\o}, \{Anne B\} and Kristian Wachtell",

year = "2012",

doi = "10.1016/j.ahj.2012.01.026",

language = "English",

volume = "163",

pages = "690--696",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Elsevier",

number = "4",

}

Bang, CN, Greve, A, Boman, K, Egstrup, K, Gohlke-Baerwolf, C, Køber, LV, Nienaber, CA, Ray, S, Rossebø, AB & Wachtell, K 2012, 'Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study', American Heart Journal, bind 163, nr. 4, s. 690-696. https://doi.org/10.1016/j.ahj.2012.01.026

TY - JOUR

T1 - Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis

T2 - the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study

AU - Bang, Casper N

AU - Greve, Anders

AU - Boman, Kurt

AU - Egstrup, Kenneth

AU - Gohlke-Baerwolf, Christa

AU - Køber, Lars Valeur

AU - Nienaber, Christoph A

AU - Ray, Simon

AU - Rossebø, Anne B

AU - Wachtell, Kristian

PY - 2012

Y1 - 2012

N2 - Lipid-lowering drugs, particularly statins, have anti-inflammatory and antioxidant properties that may prevent atrial fibrillation (AF). This effect has not been investigated on new-onset AF in asymptomatic patients with aortic stenosis (AS).

AB - Lipid-lowering drugs, particularly statins, have anti-inflammatory and antioxidant properties that may prevent atrial fibrillation (AF). This effect has not been investigated on new-onset AF in asymptomatic patients with aortic stenosis (AS).

KW - Aged

KW - Aged, 80 and over

KW - Anticholesteremic Agents

KW - Aortic Valve Stenosis

KW - Atrial Fibrillation

KW - Azetidines

KW - Double-Blind Method

KW - Female

KW - Heart Ventricles

KW - Humans

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Prognosis

KW - Simvastatin

KW - Stroke

KW - Time Factors

U2 - 10.1016/j.ahj.2012.01.026

DO - 10.1016/j.ahj.2012.01.026

M3 - Journal article

C2 - 22520536

SN - 0002-8703

VL - 163

SP - 690

EP - 696

JO - American Heart Journal

JF - American Heart Journal

IS - 4

ER -

Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study

Abstract

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater